Target Information

Target General Infomation
Target ID
T69494
Former ID
TTDS00135
Target Name
NMDA receptor
Target Type
Successful
Disease Anaesthesia; Anxiety disorder [ICD9:338, 300, 311; ICD10: R52, G89, F32, F40-F42]
Anesthesia [ICD9: 338; ICD10: R20.0]
Acute ischemic stroke [ICD9: 434.91; ICD10: I61-I63]
Acute pain [ICD9: 338,780; ICD10: R52, G89]
Alzheimer disease [ICD9: 331; ICD10: G30]
Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Cerebral infarction [ICD10: I63]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89]
Dementia [ICD9: 290-294; ICD10: F01-F07]
Depression [ICD9: 311; ICD10: F30-F39]
Exogenous obesity [ICD10: E66]
Epileptic seizures; Alzheimer disease [ICD9:345.9, 780.3, 331; ICD10: G40, P90, R56, G30]
Epilepsy [ICD10: G40]
Epileptic seizures [ICD9: 345.9, 780.3; ICD10: G40, P90, R56]
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32]
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89]
Neuropathy [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Neurodegenerative disease [ICD9: 330-337; ICD10: G30-G32]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Obsessive compulsive disorder [ICD9: 300.3; ICD10: F42]
Parkinson's disease [ICD9: 332; ICD10: G20]
Painful diabetic neuropathy [ICD9: 250.6,338,780; ICD10: E10.4, E11.4, E13.4, G89, R52]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Suicidal ideation [ICD10: R45.8]
Schizophrenia [ICD9: 295; ICD10: F20]
Schizophrenia; Indigestion [ICD9:295; ICD10: F20, K30]
Traumatic brain injury [ICD9: 800.0-801.9, 803.0-804.9, 850.0-854.1; ICD10: S06]
BioChemical Class
Ion transport
Target Validation
T69494
Drugs and Mode of Action
Drug(s) Benzphetamine Drug Info Approved Exogenous obesity [1]
D-cycloserine Drug Info Approved Bacterial infections [2]
Felbamate Drug Info Approved Epilepsy [3], [4]
Huperzine A Drug Info Approved Epileptic seizures; Alzheimer disease [5], [1]
Ketamine Drug Info Approved Anesthesia [6], [7]
L-Glutamic Acid Drug Info Approved Schizophrenia; Indigestion [8], [9], [1]
Magnesium Drug Info Approved Acute ischemic stroke [10]
Magnesium Sulfate Drug Info Approved Acute pain [10]
Memantine Drug Info Approved Alzheimer disease [11], [12]
Nitrous oxide Drug Info Approved Anaesthesia; Anxiety disorder [13], [1]
Orphenadrine Drug Info Approved Parkinson's disease [14], [15]
Amitriptyline+ketamine Drug Info Phase 3 Neuropathic pain [16]
Dexanabinol Drug Info Phase 3 Traumatic brain injury [17]
Remacemide Drug Info Phase 3 Pain [18]
AV-101 Drug Info Phase 2 Neuropathic pain [19]
CHF-3381 Drug Info Phase 2 Neuropathic pain [20], [21]
CNS-5161 Drug Info Phase 2 Neuropathic pain [21]
D-cycloserine Drug Info Phase 2 Obsessive compulsive disorder [2]
Dextromethorphan+quinidine Drug Info Phase 2 Painful diabetic neuropathy [22]
Dimiracetam Drug Info Phase 2 Neuropathic pain [23]
MDL-27192 Drug Info Phase 2 Epileptic seizures [24]
Neramexane Drug Info Phase 2 Cancer pain [25]
NRX-1074 Drug Info Phase 2 Major depressive disorder [26]
TRAXOPRODIL MESYLATE Drug Info Phase 2 Neurological disease [27]
ADCI Drug Info Phase 1 Epileptic seizures [28]
ASP-0777 Drug Info Phase 1 Alzheimer disease [29]
AZD6423 Drug Info Phase 1 Suicidal ideation [30]
AD-529 Drug Info Preclinical Neuropathic pain [31]
ADX-2 series Drug Info Preclinical Schizophrenia [32]
ED-1812 Drug Info Preclinical Pain [31]
Midafotel Drug Info Discontinued in Phase 3 Cognitive disorders [33]
Selfotel Drug Info Discontinued in Phase 3 Cerebrovascular ischaemia [34], [35]
AZD6765 Drug Info Discontinued in Phase 2 Major depressive disorder [36], [37]
EAA-090 Drug Info Discontinued in Phase 2 Painful diabetic neuropathy [21]
SGS-111 Drug Info Discontinued in Phase 2 Cognitive disorders [38]
CGP-37849 Drug Info Discontinued in Phase 1 Neurological disease [39], [40]
Delucemine Drug Info Discontinued in Phase 1 Depression [41]
S-1746 Drug Info Discontinued in Phase 1 Cerebrovascular ischaemia [42]
ACEA-1011 Drug Info Terminated Cerebral infarction [43]
ACEA-1031 Drug Info Terminated Cerebrovascular ischaemia [44]
ACEA-1328 Drug Info Terminated Cancer pain [45]
ACEA-1416 Drug Info Terminated Cerebrovascular ischaemia [46]
CNS-1531 Drug Info Terminated Neuropathy [47]
CNS-5788 Drug Info Terminated Cerebrovascular ischaemia [48]
Dextrorphan Drug Info Terminated Acute ischemic stroke [49]
FR-115427 Drug Info Terminated Cerebrovascular ischaemia [50]
GPI-3000 Drug Info Terminated Cerebrovascular ischaemia [51]
IDRA-21 Drug Info Terminated Alzheimer disease [52], [53]
L-689560 Drug Info Terminated Neurodegenerative disease [54], [55]
L-698544 Drug Info Terminated Alzheimer disease [56]
LY-274614 Drug Info Terminated Dementia [57]
M-241247 Drug Info Terminated Cerebrovascular ischaemia [58]
NPS-1392 Drug Info Terminated Cerebrovascular ischaemia [59]
PD-158473 Drug Info Terminated Cerebrovascular ischaemia [60]
PD-159913 Drug Info Terminated Cerebrovascular ischaemia [61]
Modulator ACEA-1011 Drug Info [62]
ACEA-1031 Drug Info [63]
ACEA-1416 Drug Info [64]
ACPC Drug Info [65], [1]
ADCI Drug Info [28]
ASP-0777 Drug Info [66]
CGP-37849 Drug Info [67]
CNS-1531 Drug Info [68]
Delucemine Drug Info [69]
FR-115427 Drug Info [70]
GPI-3000 Drug Info [71]
IDRA-21 Drug Info [53]
L-689560 Drug Info [72]
L-698544 Drug Info [73]
LY-274614 Drug Info [74]
MDL-27192 Drug Info [75], [1]
Memantine Drug Info [76], [1]
Midafotel Drug Info [77]
PD-158473 Drug Info [78]
PD-159913 Drug Info [68]
SGS-111 Drug Info [79]
TRAXOPRODIL MESYLATE Drug Info [80], [1]
Antagonist ACEA-1328 Drug Info [25]
AD-529 Drug Info [68]
ADX-2 series Drug Info [32]
Amitriptyline+ketamine Drug Info [21]
Aptiganel HCl Drug Info [81]
AV-101 Drug Info [82]
AZD6423 Drug Info [83]
AZD6765 Drug Info [84]
Benzphetamine Drug Info [85]
C-101,606 Drug Info [86]
CHF-3381 Drug Info [21]
CNS-5161 Drug Info [21]
CNS-5788 Drug Info [87]
Dexanabinol Drug Info [17]
Dextromethorphan+quinidine Drug Info [21]
Dextrorphan Drug Info [81]
Dimiracetam Drug Info [88]
EAA-090 Drug Info [21]
ED-1812 Drug Info [68]
Felbamate Drug Info [89], [90], [91]
Huperzine A Drug Info [92]
Ketamine Drug Info [93], [94], [95]
L-Glutamic Acid Drug Info [96]
M-241247 Drug Info [97]
Magnesium Drug Info [10]
Magnesium Sulfate Drug Info [98]
Neramexane Drug Info [25]
Nitrous oxide Drug Info [13]
NPS-1392 Drug Info [99]
Orphenadrine Drug Info [100], [101]
S-1746 Drug Info [102]
Selfotel Drug Info [81]
Agonist D-cycloserine Drug Info [103], [2]
NRX-1074 Drug Info [104]
Remacemide Drug Info [81], [93]
References
REF 1Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 2Has nature already identified all useful antibacterial targets? Curr Opin Microbiol. 2008 Oct;11(5):387-92. Epub 2008 Oct 6.
REF 3Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
REF 4(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5473).
REF 5Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000687)
REF 6(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4233).
REF 7Calcium channel blockers in the spectrum of antihypertensive agents. Expert Opin Pharmacother. 2006 Dec;7(17):2385-401.
REF 8Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
REF 9(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1369).
REF 10Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
REF 11(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4253).
REF 12Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):133-7.
REF 13Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
REF 14FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040249.
REF 15(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7251).
REF 16A Phase III Randomized, Placebo-Controlled Study of Topical Amitriptyline and Ketamine for Chemotherapy-Induced Peripheral Neuropathy (CIPN): A University of Rochester CCOP Study of 462 Cancer Survivors. Support Care Cancer. 2014 July; 22(7): 1807-1814.
REF 17Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
REF 18Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J Pharmacol Exp Ther. 1996 Jan;276(1):161-8.
REF 19ClinicalTrials.gov (NCT02484456) Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder.
REF 20Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44.
REF 21Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
REF 22Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
REF 23ClinicalTrials.gov (NCT01135251) Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy. U.S. National Institutes of Health.
REF 24Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005914)
REF 25Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
REF 26ClinicalTrials.gov (NCT02067793) Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder. U.S. National Institutes of Health.
REF 27ClinicalTrials.gov (NCT00163059) The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD. U.S. National Institutes of Health.
REF 28The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
REF 29ClinicalTrials.gov (NCT01406145) A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil. U.S. National Institutes of Health.
REF 30ClinicalTrials.gov (NCT01926366) AZD6423 SAD/MAD Study in Healthy Volunteers. U.S. National Institutes of Health.
REF 31Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022365)
REF 32The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.
REF 33Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002722)
REF 34(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4155).
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001276)
REF 36(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7681).
REF 37Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026805)
REF 38Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017512)
REF 39(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4154).
REF 40Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007917)
REF 41Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009310)
REF 42Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016496)
REF 43Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007916)
REF 44Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008256)
REF 45Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007690)
REF 46Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007961)
REF 47Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001975)
REF 48Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013711)
REF 49Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009336)
REF 50Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009401)
REF 51Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001817)
REF 52(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4219).
REF 53IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
REF 54(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4239).
REF 55Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001828)
REF 56Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003218)
REF 57Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001393)
REF 58Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
REF 59Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013127)
REF 60Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008060)
REF 61Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008061)
REF 62NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4.
REF 63In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81.
REF 64Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr;37(4):295-302.
REF 651-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8.
REF 66US patent application no. 2011,0262,442, Compositions for treating cns disorders.
REF 67The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6.
REF 68WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
REF 69NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann N Y Acad Sci. 1999;890:450-7.
REF 70Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995 Feb 9;185(2):107-10.
REF 71Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke. 1998 Apr;29(4):824-9.
REF 72Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992 May;41(5):923-30.
REF 733-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408.
REF 74The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75.
REF 75Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54.
REF 76The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
REF 77D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci Lett. 1990 Jun 8;113(3):315-21.
REF 78Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J Pharm Sci. 2002 Dec;91(12):2579-87.
REF 79Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010 February; 31(2): 66.
REF 80J Neurotrauma. 2005 Dec;22(12):1428-43.The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury.
REF 81Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
REF 82Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc.
REF 83Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009.
REF 84Clinical pipeline report, company report or official report of AstraZeneca (2009).
REF 85Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
REF 86Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001 Jan;1(1):13-8.
REF 87Identification and characterization of a potential ischemia-selective N-methyl-D-aspartate (NMDA) receptor ion-channel blocker, CNS 5788. Bioorg Med Chem Lett. 2001 Feb 26;11(4):501-4.
REF 88Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94.
REF 89Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85-110.
REF 90Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model. Pharmacology. 2008;81(3):259-65. Epub 2008 Feb 4.
REF 91Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. Epub 2008 Feb 27.
REF 92Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. Epub 2008 Nov 12.
REF 93Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
REF 94Ketamine Modulates Theta and Gamma Oscillations. J Cogn Neurosci. 2009 Jul 7.
REF 95Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91.
REF 96Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008 Dec;165(12):1594-603. Epub 2008 Oct 15.
REF 97Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
REF 98Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
REF 99Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1915-20.
REF 100Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. Epub 2009 Feb 12.
REF 101Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. 1997 Jul;21(4):393-400.
REF 1021,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77.
REF 103How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30.
REF 104Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci. 2013 Nov 20;7:218.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.